







<p>DECEMBER 2019</p>	<p>JANUARY 10/11, 2020</p>	<p>JANUARY 10 - JANUARY 23, 2020</p>	<p>JANUARY 23, 2020</p>
<p>INOVIO coronavirus experts learn about a novel coronavirus (SARS-CoV-2) that caused an outbreak of respiratory disease in Wuhan, China, now referred to as COVID-19</p>	<p>Chinese researchers share the genetic sequence of the novel coronavirus on 1/10</p> <p>INOVIO designs DNA vaccine INO-4800 in three hours after receiving the genetic sequence late in the evening on 1/10 using its proprietary DNA medicines platform technology</p> <p>INO-4800 was designed just after midnight on 1/11 to precisely match the DNA sequence of the virus</p>	<p>INOVIO coronavirus experts race to manufacture INO-4800 and begin preclinical testing and clinical trial design</p>	<p>INOVIO receives a grant of up to \$9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to fund ongoing preclinical and initial clinical development of INO-4800</p> 
<p>MARCH 2020</p>	<p>MARCH 12, 2020</p>	<p>MARCH 26, 2020</p>	<p>APRIL 6 - APRIL 23, 2020</p>
<p>Ongoing preclinical studies, including challenge studies; human clinical trial designs finalized; 3,000 human trial doses prepared for clinical trials in the U.S., China, and South Korea; large-scale manufacturing plans developed</p>	<p>INOVIO announces \$5 million grant from the Bill &amp; Melinda Gates Foundation to continue advancing the development of INO-4800, specifically to accelerate the testing and scale up of INOVIO's proprietary smart device CELLECTRA® 3PSP</p> 	<p>INOVIO announces the Department of Defense (DoD) awarded Ology Bioservices an \$11.9 million contract to work with INOVIO on DNA technology transfer to rapidly manufacture INO-4800 for the DoD for upcoming clinical trials</p> 	<p>INOVIO announces initiation of Phase 1 human clinical trial in the U.S. following authorization by the U.S. Food and Drug Administration of its Investigational New Drug (IND) application</p> <p>U.S. study fully enrolls 40 healthy volunteers; study sites are the University of Pennsylvania and a clinic in Kansas City, MO</p> <p>Clinical trials and preclinical challenge studies continue</p>
<p>MAY 20, 2020</p>	<p>JUNE/JULY 2020</p>	<p>SEPTEMBER 2020</p>	<p>ONGOING</p>
<p>Preclinical data (in mice and guinea pigs) published in peer-reviewed journal Nature Communications</p>  <p>Clinical trials and preclinical challenge studies continue</p>	<p>Phase 1 trial expanded with 80 additional participants (older adults, low-dose arm)</p> <p>INOVIO receives \$71 million from DoD to scale up manufacture of CELLECTRA 3PSP and procurement of CELLECTRA® 2000 (6/23)</p>  <p>INOVIO announces positive interim Phase 1 data for INO-4800 (6/30); durable antibody and T cell responses in NHPs challenged with SARS-CoV-2 (7/30)</p> <p>Phase 1/2 trials begin in South Korea, China</p>	<p>Phase 2/3 trials expected to begin*</p>	<p>INO-4800 COVID-19 DNA vaccine production and scale up underway*</p> 

\*Pending appropriate regulatory guidance and external funding